Placental mesenchymal stem cells seeded on a commercially available dural graft extracellular matrix (DrugBank: Placental Mesenchymal Stem Cells)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 118 | 脊髄髄膜瘤 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04652908 (ClinicalTrials.gov) | February 2021 | 25/11/2020 | Cellular Therapy for In Utero Repair of Myelomeningocele - The CuRe Trial | Phase 1/2a Trial of Placental Mesenchymal Stem Cells for Repair of Fetal Myelomeningocele | Myelomeningocele | Biological: Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix | Diana Lee Farmer | California Institute for Regenerative Medicine (CIRM) | Not yet recruiting | 19 Weeks | 25 Weeks | All | 35 | Phase 1;Phase 2 | NULL |